Clinical trials
Phase 1 Glaucoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 33 |
| Active, not recruiting | 3 |
| Unknown status | 3 |
| Recruiting | 2 |
| Terminated | 2 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Chong Kun Dang Pharmaceutical | 2 |
| Johns Hopkins University | 2 |
| Laboratorios Sophia S.A de C.V. | 2 |
| Shahid Beheshti University of Medical Sciences | 2 |
| Stanford University | 2 |
| Alcon Research | 1 |
| Amakem, NV | 1 |
| Care Team Solutions | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Dompé Farmaceutici S.p.A | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glaucoma | 46 |
| Ocular Hypertension | 15 |
| Glaucoma, Open-Angle | 6 |
| Eye Diseases | 5 |
| Hydrophthalmos | 2 |
| Cataract | 1 |
| Disease | 1 |
| Optic Nerve Injuries | 1 |
| Optic Neuropathy, Ischemic | 1 |
| Uveitis | 1 |
Trials
Showing 26 to 46 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.